RESEARCH
20 Sep 2025
Approval of elamipretide and Mirum Pharma deal point to growing investor interest in high-need therapies with small patient populations
TECHNOLOGY
13 May 2026
INSIGHTS
30 Oct 2025
PARTNERSHIPS
2 Jun 2026
INVESTMENT
1 Jun 2026
INNOVATION
29 May 2026
MARKET TRENDS
28 May 2026
3 Jun 2026
Travere licenses civorebrutinib from Everest in $1.14B deal targeting rare immune-mediated kidney diseases
1 Feb 2025
Tailored antisense drugs move from concept to clinic as researchers and companies test faster models for ultra-rare conditions
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.